Coronavirus: NAFDAC gives approval for the Production Of chloroquine for clinical trials
The National Agency for Food and Drug Administration and Control (NAFDAC) has approved the production of Chloroquine for clinical trials in order to curb the widespread COVID-19.
This was revealed by the Director-General of the agency at the headquarters in Lagos earlier today.
She, also clarified that NAFDAC is not approving Chloroquine for the treatment of COVID-19 but for clinical trials to find treatment for the virus.
“In the case of Chloroquine, it has been demonstrated in the literature and with clinical research which is still ongoing, that Chloroquine is superior to the Placebo.
“NAFDAC is not approving Chloroquine as a product that has can be used for Coronavirus because there is no submission to us for registration but because it is under clinical trials, NAFDAC approves medicines meant for clinical trials.
“Therefore the medicine is being approved just for the clinical trials,” Adeyeye announced.
Comments